Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG and Etanercept in Early Stage MDS
NCT00217386Phase 2Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Mar 2004
- Primary completion
- Dec 2007
- Modality
- Antibody-Based Therapeutics, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of antithymocyte globulin rabbit and etanercept in myelodysplastic syndrome (MDS), sponsored by Fred Hutchinson Cancer Center. Primary endpoints: Response Rate, Correlation of ex vivo and in vitro phenotypic, cytogenetic, and functional disease characteristics with in vivo response and 1 more. Started Mar 2004; status: completed.
02
Drugs
antithymocyte globulin rabbitetanercept
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT00217386.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00217386.